Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Investors who bought VTGN during the stated period have until March 16, 2026 to seek lead-plaintiff status.

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

Regeneron’s Garetosmab Slashes New Bone Lesions in FOP Phase 3, U.S. Filing Planned This Year

Maze Therapeutics Reports Strong Phase 1 Signal for MZE782, Announces $150 Million Private Placement